These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37753656)

  • 1. Regional Social Vulnerability is Associated With Geographic Disparity in Waitlist Outcomes for Patients With Non-Hepatocellular Carcinoma Model for End-stage Liver Disease Exceptions in the United States.
    Cannon RM; Goldberg DS; Sheikh SS; Anderson DJ; Pozo M; Rabbani U; Locke JE
    Ann Surg; 2024 May; 279(5):825-831. PubMed ID: 37753656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
    Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
    J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
    Ishaque T; Beckett J; Gentry S; Garonzik-Wang J; Karhadkar S; Lonze BE; Halazun KJ; Segev D; Massie AB
    Transplantation; 2024 Aug; 108(8):e170-e180. PubMed ID: 38548691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCC patients suffer less from geographic differences in organ availability.
    Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
    Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MELD Exceptions and Rates of Waiting List Outcomes.
    Massie AB; Caffo B; Gentry SE; Hall EC; Axelrod DA; Lentine KL; Schnitzler MA; Gheorghian A; Salvalaggio PR; Segev DL
    Am J Transplant; 2011 Nov; 11(11):2362-71. PubMed ID: 21920019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses.
    Wey A; Noreen S; Gentry S; Cafarella M; Trotter J; Salkowski N; Segev D; Israni A; Kasiske B; Hirose R; Snyder J
    Liver Transpl; 2022 Mar; 28(3):363-375. PubMed ID: 34482614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Travel distance and social vulnerability index: Impact on liver-related mortality among patients with end-stage liver disease.
    Yang J; Endo Y; Moazzam Z; Lima HA; Woldesenbet S; Alaimo L; Azap L; Shaikh CF; Munir MM; Katayama E; Sasaki K; Pawlik TM
    Clin Transplant; 2023 Sep; 37(9):e15001. PubMed ID: 37126400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
    Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
    Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions.
    Bittermann T; Goldberg DS; Bauer CM; Khungar V
    Transplantation; 2017 May; 101(5):1099-1105. PubMed ID: 28121908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.
    Nadim MK; DiNorcia J; Ji L; Groshen S; Levitsky J; Sung RS; Kim WR; Andreoni K; Mulligan D; Genyk YS
    J Hepatol; 2017 Sep; 67(3):517-525. PubMed ID: 28483678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
    Goldberg DS; Makar G; Bittermann T; French B
    Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Region 11 MELD Na exception prospective study.
    Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
    Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation.
    Raza MH; Kwon Y; Kobierski P; Misra AC; Lim A; Goldbeck C; Etesami K; Kohli R; Emamaullee J
    Liver Transpl; 2023 Feb; 29(2):134-144. PubMed ID: 35876731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.